Back to top

MTN-013 was a Phase I safety and drug absorption study that tested 28-day use of vaginal rings containing either dapivirine, maraviroc, or the two ARVs combined, and was conducted among 48 women at three U.S. sites. The study was the first clinical trial of a vaginal ring containing maraviroc, and the first to test a vaginal ring with two active drugs. Results, reported in 2014, found the ring was safe in women and evidence of dapivirine in cervical tissue and blood. In addition, laboratory tests of tissues samples showed that dapivirine was able to block HIV infection, though levels of maraviroc were not sufficient to have a similar effect.

First Trial of Combination ARV Vaginal Ring for HIV Prevention Finds Ring Safe but One ARV Carrying the Weight



MTN-013/IPM 026 Q&A



See Also

MTN-013/IPM 026 Protocol


MTN-013 Study Page


First Combination ARV Vaginal Ring for HIV Prevention Being Tested in Phase I Safety Trial